{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:04:36Z","timestamp":1787497476227,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.atherosclerosis.2020.11.025","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T11:02:33Z","timestamp":1606561353000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study"],"prefix":"10.1016","volume":"316","author":[{"given":"Azin","family":"Kheirkhah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rantner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8889-8315","authenticated-orcid":false,"given":"Barbara","family":"Kollerits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Pohlhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Klein-Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Fraedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-1120","authenticated-orcid":false,"given":"Florian","family":"Kronenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2018.05.033","article-title":"Update on peripheral artery disease: epidemiology and evidence-based facts","volume":"275","author":"Shu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.tvir.2016.04.001","article-title":"Epidemiology of peripheral arterial disease and critical limb ischemia","volume":"19","author":"Dua","year":"2016","journal-title":"Tech. Vasc. Intervent. Radiol."},{"issue":"Suppl S","key":"10.1016\/j.atherosclerosis.2020.11.025_bib3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/2047487313519344","article-title":"Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study","volume":"22","author":"Subherwal","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib5","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","article-title":"Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease","volume":"120","author":"Diehm","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2014.08.032","article-title":"Correlation between a positive family risk score and peripheral artery disease in one case-control and two population-based studies","volume":"237","author":"Lamina","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2019.11.006","article-title":"Finally, the big picture of morbidity and mortality in peripheral arterial disease?","volume":"293","author":"Zierfuss","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2018.04.032","article-title":"Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate","volume":"274","author":"Kostner","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R071571","article-title":"Lipoprotein (a): a historical appraisal","volume":"58","author":"Kostner","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib11","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/eurheartj\/ehaa420","article-title":"Mechanistic insights into lipoprotein(a): from infamous to \u201cinflammous","volume":"41","author":"Coassin","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein(a) concentrations, apolipoprotein(a) phenotypes and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib13","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1373\/clinchem.2007.088013","article-title":"Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease","volume":"53","author":"Dieplinger","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.amjcard.2010.01.370","article-title":"Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study)","volume":"105","author":"Volpato","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41591-019-0492-5","article-title":"Genome-wide association study of peripheral artery disease in the million veteran program","volume":"25","author":"Klarin","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MOL.0000000000000641","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?","volume":"30","author":"Boffa","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib20","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2008.03.009","article-title":"Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease","volume":"202","author":"Folsom","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.003497","article-title":"Plasma levels of proprotein convertase subtilisin\/kexin type 9 are elevated in patients with peripheral artery disease and associated with metabolic disorders and dysfunction in circulating progenitor cells","volume":"5","author":"Chao","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2018.07.030","article-title":"The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia","volume":"277","author":"Cao","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001992","article-title":"Genetic regulation of PCSK9 (proprotein convertase subtilisin\/kexin type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes","volume":"11","author":"Pott","year":"2018","journal-title":"Circ. Genomic Precis. Med."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1373\/clinchem.2007.102046","article-title":"Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study","volume":"54","author":"Rantner","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib26","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/ATVBAHA.118.310865","article-title":"Genetic factors explain a major fraction of the 50% lower lipoprotein[a] concentrations in Finns","volume":"38","author":"Erhart","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0022-2275(20)39975-2","article-title":"Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides","volume":"35","author":"Kronenberg","year":"1994","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1523-1755.2004.00737.x","article-title":"Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy?","volume":"66","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/eurheartj\/eht484","article-title":"In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study","volume":"35","author":"Cheng","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102034","article-title":"New insights into the role of inflammation in the pathogenesis of atherosclerosis","volume":"18","author":"Wu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib33","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib37","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"Van Der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib40","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2019.07.003","article-title":"Therapeutic lowering of lipoprotein(a): how much is enough?","volume":"288","author":"Kronenberg","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib43","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic to Transl. Sci"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/eurheartj\/ehv568","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 levels and the risk of first cardiovascular events","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40618-016-0433-9","article-title":"Analysis of the association between plasma PCSK9 and lp(a) in han Chinese","volume":"39","author":"Yang","year":"2016","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.atherosclerosis.2016.08.038","article-title":"PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia","volume":"254","author":"Alonso","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib48","first-page":"56390","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 (PCSK9) is independently associated with insulin resistance, triglycerides, lipoprotein(a) levels but not low-density lipoprotein cholesterol levels in a general population","author":"Hamamura","year":"2020","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2020.11.025_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-016-0339-8","article-title":"Correlation between serum levels of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease","volume":"15","author":"Nozue","year":"2016","journal-title":"Lipids Health Dis."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020315343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020315343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:44:16Z","timestamp":1758156256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020315343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":49,"alternative-id":["S0021915020315343"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.11.025","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}